Companies › XellSmart Bio-Pharmaceutical (Suzhou)
3 active drug programs in 3 registered trials: 3 Phase 1; Neurology; next expected readout Jan 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| XS228CN Human allogeneic iPSC-derived motor neuron progenitor cells | – | Phase 1 | Amyotrophic Lateral Sclerosis (ALS) | Jan 2027 |
| XS228 Allogeneic human induced pluripotent stem cell (iPSC)-derived motor neuron progenitor cell | – | Phase 1 | Spinal Cord Injury | Feb 2028 |
| XS411 human allogeneic induced pluripotent stem cell (iPSC)-derived dopaminergic neural progenit | – | Phase 1 | Parkinson Disease (PD) | Mar 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07118319 | XS228CN | Phase 1 | Amyotrophic Lateral Sclerosis (ALS) | Neurology | Jan 2027 |
| NCT06976229 | XS228 | Phase 1 | Spinal Cord Injury | Neurology | Feb 2028 |
| NCT07166757 | XS411 | Phase 1 | Parkinson Disease (PD) | Neurology | Mar 2028 |
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.